WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)

類似資料

• WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
  著者:: Jonathan Barratt, 等
  出版事項: (2025-02-01)
• WCN24-1868 ASSIST: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I
  著者:: Irene L. Noronha, 等
  出版事項: (2024-04-01)
• WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
  著者:: Dmitrij Kollins, 等
  出版事項: (2025-02-01)
• WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
  著者:: Dmitrij Kollins, 等
  出版事項: (2025-02-01)
• WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
  著者:: Chee Kay Cheung, 等
  出版事項: (2025-02-01)